Inflammatory cells and immune microenvironment in malignant lymphoma

Journal of Internal Medicine

Volumn 264, Issue 6, 2008, Pages 528-536

  De Jong, D ^a   Enblad, G ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Department of Oncology Radiology and Clinical Immunology ^*  (Sweden)

Author keywords

Adaptive immune response; B cell lymphoma; Classical Hodgkin Lymphoma; Immune microenvironment; Innate immune response; Oncogenesis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CARCINOGENESIS; CELL ACTIVATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TRANSLOCATION; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INFLAMMATORY CELL; INNATE IMMUNITY; LARGE CELL LYMPHOMA; MICROENVIRONMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

CELL PROLIFERATION; CYTOKINES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; T-LYMPHOCYTES, REGULATORY;

EID: 55949108741     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02032.x     Document Type: Conference Paper

References (64)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002 420 : 860 7.
2. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004 22 : 329 60.
3. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006 6 : 24 37.
4. Zou W. Regulatory T-cells tumour immunity and immunotherapy. Nat Rev Immunol 2006 6 : 295 307.
5. Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007 7 : 880 7.
6. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2004 24 : 995 1007.
7. Leich E, Hartmann EM, Burek C, Ott G, Rosenwald A. Diagnostic and prognostic significance of gene expression profiling in lymphomas. APMIS 2007 115 : 1135 46.
8. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by hoist inflammatory response. Blood 2006 105 : 1851 61.
9. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002 246 : 1937 47.
10. Chang K-C, Huang G-C, Jones D, Lin Y-H. Distribution patterns of dendritic cells and T-cells in diffuse large B-cell lymphomas correlate with prognosis. Clin Cancer Res 2007 12 : 6666 72.
11. van Imhoff GW, Boerma EJG, van der Holt B et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006 24 : 4135 42.
12. Muris JJF, Meijer CJLM, Cilessen SAGM et al. Prognostic significance of activated cytotoxic T-lymphocytes in prmary nodal diffuse large B-cell lymphoma. Leukemia 2004 18 : 589 96.
13. Hasselblom S, Sigursdottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson P-O. The number of tumour-infiltrating TIA1+ cytotoxic T cells but not FoxP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007 137 : 364 73.
14. Booman M, Douwes J, Glas AM et al. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res 2006 12 : 2698 705.
15. Rimza LM, Roberts RA, Campo E et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006 107 : 1101 7.
16. Rimza LM, Roberts RA, Miller TP et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumour immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2003 103 : 4251 8.
17. Rimsza LM, Farinha P, Fuchs DA, Masoudi H, Connors JM, Gascoyne RD. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 2007 48 : 542 6.
18. Lee NR, Song EK, Jang KY et al. Prognostic impact of tumour infiltrating FoxP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008 49 : 247 56.
19. Tzankov A, Meier C, Hirschmann P, Went P, Pileri S. Correlation of high numbers of intratumoural FoxP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's disease. Haematologica 2008 93 : 193 200.
20. Hedstrom G, Berglund M, Molin D et al. Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2007 138 : 68 71.
21. Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993 342 : 575 7.
22. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007 136 : 521 38.
23. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005 23 : 6370 8.
24. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low- grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996 178 : 122 7.
25. Hussell T, Isaacson PG, Crabtree JE, Dogan A, Spencer J. Immunoglobulin specificity of low grade B cell gastrointestinal lymphoma of mucosa-associated lymphoid tissue (MALT) type. Am J Pathol 1993 142 : 285 92.
26. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997 24 : 457 61.
27. Chanudet E, Zhou Y, Bacon CM et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol 2006 209 : 344 51.
28. Lecuit M, Abachin E, Martin A et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004 350 : 239 48.
29. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005 23 : 6358 63.
30. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia 2008 22 : 49 58.
31. Glas AM, Knoops L, Delahaye L et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007 25 : 390 8.
32. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumour-infiltrating immune cells. N Engl J Med 2004 351 : 2159 69.
33. Glas AM, Kersten MJ, Delahaye LJ et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005 105 : 301 7.
34. Farinha P, Masoudi H, Skinnider BF et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005 106 : 2169 74.
35. Lee AM, Clear AJ, Calaminici M et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006 24 : 5052 9.
36. Alvaro T, Lejeune M, Salvado M-T et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behaviour in follicular lymphoma patients. J Clin Oncol 2006 24 : 5350 7.
37. Carreras J, Lopez-Guillermo A, Fox BC et al. High numbers of tumour-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006 108 : 2957 64.
38. Klapper W, Hoster E, Rolver L et al. Tumour sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol 2007 25 : 3330 6.
39. Kelley T, Beck R, Absi A et al. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma 2007 48 : 2403 11.
40. Wahlin BE, Sander B, Christensson B et al. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007 13 : 388 97.
41. Taskinen M, Karjalainen-Lindsberg M-L, Nyman H et al. A high tumour-associated macrophage content predicts favourable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin- vincristine-prednisone. Clin Cancer Res 2007 13 : 5784 9.
42. Taskinen M, Karjalainen-Lindsberg ML, Leppä S. Prognostic influence of tumour-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 2008 111 : 4664 7.
43. Canioni D, Salles G, Mounier N et al. High numbers of tumour-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008 26 : 440 6.
44. Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005 106 : 2018 2.
45. Knoops L, Haas R, de Kemp S et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007 110 : 1116 22.
46. Kuppers R, Rajewsky K, Zhao M et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 1994 91 : 10962.
47. Gruss HJ, Pinto A, Duyster J et al. Hodgkin's disease: a tumour with disturbed immunological pathways. Immunol Today 1997 18 : 156.
48. Fischer M, Harvima IT, Carvalho RF et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006 116 : 2748.
49. Enblad G, Sundstrom C, Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993 11 : 187.
50. Toth J, Dworak O, Sugar J. Eosinophil predominance in Hodgkin's disease. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1977 89 : 107.
51. Crocker J, Smith PJ. A quantitative study of mast cells in Hodgkin's disease. J Clin Pathol 1984 37 : 519.
52. Molin D, Fischer M, Xiang Z et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001 114 : 616.
53. Sharma VK, Agrawal A, Pratap VK et al. Mast cell reactivity in lymphoma: a preliminary communication. Indian J Cancer 1992 29 : 61.
54. Pinto A, Aldinucci D, Gloghini A et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996 88 : 3299.
55. Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990 75 : 13.
56. Glimelius I, Edstrom A, Amini RM et al. IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol 2006 76 : 278.
57. Endo MUK, Kitazume K, Iwabe K, Okuyama Y, Urabe A. Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor. Ann Hematol 1995 71 : 313.
58. Fischer M, Juremalm M, Olsson N et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003 107 : 197.
59. Jundt F, Anagnostopoulos I, Bommert K et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999 94 : 2065.
60. von Wasielewski R, Seth S, Franklin J et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000 95 : 1207.
61. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol 1996 157 : 3635.
62. Sanchez-Aguilera A, Montalban C, de la Cueva P et al. Tumour microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006 108 : 662.
63. Alvaro A, Sola R, Rosales R et al. Gene expression analysis of a human enterocyte cell line reveals downregulation of cholesterol biosynthesis in response to short-chain fatty acids. IUBMB Life 2008 [Epub ahead of print] (July).
64. Ma Y, Visser L, Blokzijl T et al. The CD4 + CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Invest 2008 88 : 482.